HEALTHIER CHINA THROUGH INNOVATION

The R&D-Based Pharmaceutical Association Committee (RDPAC), representing 47 leading multinational pharmaceutical companies with R&D capabilities, is a committee within the China Association of Enterprises with Foreign Investment (CAEFI).


Welcome, Mayoly!

December 27, 2024
RDPAC EC voted to approve the application of Mayoly to join RDPAC as of January 1, 2025.

PUBLICATIONS

DEEPENING THE DRUG INNOVATION ECOSYSTEM REFORM – A PLAN TO DESIGN AND BUILD CHINA’S CLINICAL RESEARCH SYSTEM

Health is the common aspiration of all mankind, and a healthy China constitutes an integral part of the “China Dream”.